Aplisol (tuberculin, purified protein derivative)

No dosing information is available for this tab.

Administer by intradermal injection only; do not inject IV, IM, or subcutaneously. If subcutaneous injection occurs, the test cannot be interpreted.

Store vials at 2-8oC; do not freeze and protect from light. Vials in use for more than 30 days should be discarded due to possible oxidation and degradationwhich may affect potency.

Inspect the vials for particulate matter and/or discoloration before use. If theseconditions exist, do not administer the product. Use a separate syringe and needle for each injection.

Administer by intradermal injection using the Mantoux method.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

*Patients with known hypersensitivity or allergy to tuberculin PPD or any of itscomponents.

*Manufacturer of Tubersol(R) states that the tuberculin skin test should not be administered to persons with documented active tuberculosis or a clear history of treatment of TB infection or disease, and to persons with extensive burns or eczema.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

Induration at the tuberculin PPD injection site is the expected reaction for a positive skintest; however, strongly positive reactions incuding vesiculation, ulceration, necrosis, or scarring may occur. Immediate erythematous or other reactions also may occur at the injection site.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

There is no contraindication to tuberculin skin testing of infants and children. Young children (e.g., infants <6 months ofage) who are infected with M. tuberculosis may not react to tuberculin PPD. The American Academy of Pediatricians (AAP) recommends that only children who have a risk factor for TB infection or are at risk for progressing to disease, are suspected of having TB disease, or who have immunosuppressive disease or about to start immunsuppressive therapy should be tested with either a tuberculin skin test (TST) or a TB blood test.

Animal reproduction studies have not been conducted with tuberculin PPD. It is also notknown whether the drug can cause fetal harm when administered to a pregnantwoman or can affect reproduction capacity. Tuberculin PPD should be given to a pregnantwoman only if clearly needed.

It is not known whether tuberculin PPD is excreted in human milk. Because many drugs areexcreted in human milk, caution should be exercised when tuberculin PPD is administered toa nursing woman.

Once acquired, tuberculin sensitivity tends to persist, although it often wanes with time and advancingage. In geriatric patients, the reaction maydevelop more slowly and may not be maximal until after 72 hours. A number of factors have been reported to cause a decreased ability to respond to thetuberculin test, such as elderly patients with waned sensitivity. Any condition that impairs or attenuatescell mediated immunity potentially can cause a false negative reaction, including aging.